NeuroStar Advanced Therapy Wins 2023 dotCOMM Awards
21 Agosto 2023 - 9:56AM
Neuronetics, Inc. (NASDAQ: STIM), a medical technology company
focused on designing, developing, and marketing products that
improve the quality of life for patients who suffer from
neurohealth disorders, is thrilled to announce NeuroStar Advanced
Therapy’s “Tap Into A New Possibility for Depression” campaign has
been awarded Gold by the 2023 dotCOMM Awards in the category of
Digital Marketing & Communication Campaigns.
“This award is a recognition of our efforts to not only raise
awareness about NeuroStar, but to also educate patients and guide
their path to treatment. A priority for us as a company is to make
it easy for patients to get the help they need, and to support the
physician practices that are in the trenches, fighting depression
alongside these patients each day,” stated Lisa Metzner-Rosas,
Senior Vice President, Chief Marketing Officer, of Neuronetics Inc.
“We look forward to evolving our campaign and strategy to support
even more customers and their patients this year.”
The dotCOMM Awards is an annual international competition that
honors merit in web creativity and digital communication.
Administered and judged by the Association of Marketing and
Communication Professionals (AMCP), a globally renowned and
esteemed evaluator of creative work, the awards celebrate the best
achievements in the field. There were over 2,500 entries from
throughout the United States, Canada and internationally across 241
categories.
Neuronetics’ marketing team, with creative partner Hyperquake,
has recently expanded the “Tap Into A New Possibility for
Depression” campaign, shifting the spotlight onto the inspirational
journeys of numerous patients who triumphed over depression and
found their way to recovery with the help of NeuroStar Advanced
Therapy.
For more information about NeuroStar TMS Therapy, please
visit NeuroStar.com.
About NeuroneticsNeuronetics,
Inc. believes that mental health is as important as physical
health. As a global leader in
neuroscience, Neuronetics is redefining patient and
physician expectations with its NeuroStar Advanced Therapy for
Mental Health. NeuroStar is a non-drug, noninvasive treatment that
can improve the quality of life for people suffering from
neurohealth conditions when traditional medication hasn’t helped.
NeuroStar is FDA-cleared for adults with major depressive disorder
(MDD), as an adjunct for adults with obsessive-compulsive disorder
(OCD), and to decrease anxiety symptoms in adult patients with MDD
that may exhibit comorbid anxiety symptoms (anxious depression).
NeuroStar Advanced Therapy is the leading transcranial magnetic
stimulation (TMS) treatment for MDD in adults with over 5.6 million
treatments delivered. NeuroStar is backed by the largest clinical
data set of any TMS system for depression, including the world’s
largest depression Outcomes Registry. Neuronetics is
committed to transforming lives by offering an exceptional
treatment that produces extraordinary results. For safety and
prescribing
information, www.neurostar.com.
Media
Contact:EvolveMKD646.517.4220NeuroStar@evolvemkd.com
Neuronetics (NASDAQ:STIM)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Neuronetics (NASDAQ:STIM)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024